Search results
Results from the WOW.Com Content Network
For premium support please call: 800-290-4726 more ways to reach us
VIVUS' (NAS: VVUS) stock was down 25% for November, though still up 15% for the year. Its drug Qsymia is the first obesity drug to be approved and reach the market in more than a decade, but its ...
VIVUS Inc. (NASDAQ: VVUS) reported a quarterly loss of $0.56 per share on Monday, but this was not an earnings story. VIVUS remains a developing story about its obesity drug Qsymia. Its revenue ...
We are initiating coverage of VIVUS, Inc. (VVUS) with a $10.00 price target based on our revenue forecasts for approved products. In addition to a portfolio of weight loss, exocrine pancreatic ...
Investors had high hopes for VIVUS' (NAS: VVUS) new anti-obesity drug Qsymia, but the drug debuted to lackluster sales -- and it's taking a toll on VIVUS' share price. Now, VIVUS is shifting its ...
Vivus (OTC Pink: VVUSQ) is a small pharmaceutical company headquartered in Campbell, California, working in obesity, sleep, and sexual health.Vivus developed an erectile dysfunction drug, Avanafil, that has completed Phase 3 clinical trials. [1]
A corporation can adjust its stock price by a stock split, substituting a quantity of shares at one price for a different number of shares at an adjusted price where the value of shares x price remains equivalent. (For example, 500 shares at $32 may become 1000 shares at $16.) Many major firms like to keep their price in the $25 to $75 price range.
The pieces of the puzzle are starting to fall into place for VIVUS (NASDAQ: VVUS) and its potential blockbuster anti-obesity drug, Qsymia. The drug, which was approved by the Food and Drug ...